462 related articles for article (PubMed ID: 31235620)
1. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.
Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620
[TBL] [Abstract][Full Text] [Related]
2. Integrated Genome-Wide Analysis of an Isogenic Pair of
Huang W; Hamouche JE; Wang G; Smith M; Yin C; Dhand A; Dimitrova N; Fallon JT
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033143
[TBL] [Abstract][Full Text] [Related]
3. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
[TBL] [Abstract][Full Text] [Related]
5. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane-tazobactam for the treatment of multidrug-resistant
Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE
Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260
[TBL] [Abstract][Full Text] [Related]
7. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
Shortridge D; Pfaller MA; Streit JM; Flamm RK
J Glob Antimicrob Resist; 2020 Jun; 21():60-64. PubMed ID: 31648032
[TBL] [Abstract][Full Text] [Related]
9.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
Bretonnière C; Boutoille D; Caillon J; Desessard C; Guitton C; Potel G; Jacqueline C
Int J Antimicrob Agents; 2014 Sep; 44(3):218-21. PubMed ID: 25108877
[TBL] [Abstract][Full Text] [Related]
13. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
15. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
[TBL] [Abstract][Full Text] [Related]
17. Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.
Motos A; Li Bassi G; Pagliara F; Fernandez-Barat L; Yang H; Aguilera Xiol E; Senussi T; Idone FA; Travierso C; Chiurazzi C; Amaro R; Yang M; Bobi J; Rigol M; Nicolau DP; Frigola G; Cabrera R; Ramirez J; Pelosi P; Blasi F; Antonelli M; Artigas A; Vila J; Kollef M; Torres A
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168605
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Shortridge D; Pfaller MA; Castanheira M; Flamm RK
Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
Plant AJ; Dunn A; Porter RJ
Expert Rev Anti Infect Ther; 2018 May; 16(5):367-368. PubMed ID: 29727213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
